Drug Trial Radar · NCT06717815
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 25, 2025
Primary completion
Jun 8, 2026
Study completion Jun 8, 2026
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis
Conditions
- Lupus Nephritis
Interventions
IPG11406Drug
Investigational Medical Products: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage:15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability via assessment of Adverse eventsTime frame: Up to 58 days
- Evaluate the safety and tolerability via Respiration rate of Vital SignsTime frame: Up to 58 days
- Evaluate the safety and tolerability via Heart rate of Vital SignsTime frame: Up to 58 days
- Evaluate the safety and tolerability via Blood pressure of Vital SignsTime frame: Up to 58 days
- Evaluate the safety and tolerability via Body temperature of Vital SignsTime frame: Up to 58 days
- Evaluating the safety and tolerability from Red blood cell count of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from White blood cell of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from lymphocyte count of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from hemoglobin of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from Prothrombin time of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from Activated partial thromboplastin time of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from total bilirubin concentration of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from direct bilirubin concentratio of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from ALT of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from AST of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from creatinine concentration of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from triglyceridesconcentration of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from urine protein of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from urine pH value of Laboratory ExaminationTime frame: Up to 58 days
- Evaluating the safety and tolerability from ventricular rate of ElectrocardiogramTime frame: Up to 58 days
- Evaluating the safety and tolerability from PR interval of ElectrocardiogramTime frame: Up to 58 days
- Evaluating the safety and tolerability from QRS (ms) of ElectrocardiogramTime frame: Up to 58 days
- Evaluating the safety and tolerability from QTc of ElectrocardiogramTime frame: Up to 58 days
- Evaluate the impact of oral IPG11406 on biomarkers in patients with Lupus NephritisTime frame: Up to 58 days
- Evaluate the impact of oral administration of IPG11406 on 24-hour urine protein quantitation of proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
- Evaluate the impact of oral administration of IPG11406 on estimated glomerular filtration rate of proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
- Evaluate the impact of oral administration of IPG11406 on ratio of 24-hour urine protein to urine creatinine of proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
- Evaluate the impact of oral administration of IPG11406 on proteinuria and renal function in patients with Lupus NephritisTime frame: Up to 58 days
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital Of Anhui Medical University
Hefei, Anhui, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Fujian Provincial Hospital
Fuzhou, Fujian, China
Sun Yai-sen Memorial Hospital, Sun Yai-sen University
Guangzhou, Guandong, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
Xinxiang Central Hospital
Xinxiang, Henan, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Wuhan Hospital of Traditional Chinese and Western Medicine
Wuhan, Hubei, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Nanjing DrumTower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Nantong First People's Hospital
Nantong, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Shandong Provincial Hospital
Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Jinhua Municipal Centeral Hospital Medical Group
Jinhua, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.